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Available online 08 November 2016Background:Overweight has been associatedwith an increase in inﬂammatorymarkers andwith an imbalance in
the autonomic nervous system, such as a decrease in heart rate variability (HRV). In this study we aimed to in-
vestigate the modifying effect of a genetic variation in a major anti-inﬂammatory marker gene, NFE2L2, on the
relationship between overweight and HRV.
Methods:We analyzed participants of the SAPALDIA cohort aged 50 years and older, twice in 2002/2003 (N =
1472) and 2010/2011 (N= 1235). We included persons with valid genotype data, who underwent ambulatory
24-h electrocardiogrammonitoring, and reported onmedical history and lifestyle. The association between HRV
and BMI,measured as standard deviation of normal-to-normal intervals (SDNN) by BMI and themodifying effect
of the cardiovascular health-related NFE2L2 gene variant rs2364723 were tested, applying multivariable mixed
linear regression models.
Results:We found study participants with overweight (BMI N 25) over two follow-up surveys 10 years apart to
have a negative association between SDNN, calculated as geometric means, with BMI. The examinedNFE2L2 var-
iant sustainably modiﬁed (pinteraction = 0.014) the found inverse association between a BMI increment and
SDNN, causing a stronger decrement in SDNN for participants with the CC genotype (−20.7%; 95%-conﬁdence
interval:−12.33 to−28.28) compared with participants carrying the GC (−7.43; 95%CI:−3.56 to−11.15)
or GG (−11.26%; 95%CI:−7.68 to−14.7) genotype, estimated for the difference from the 90th to the 10th per-
centile of BMI by the NFE2L2 variant.
Conclusions: Our results are consistent with the hypothesis that overweight decreases heart rate variability
through inﬂammatory processes.
© 2016 Swiss Tropical and Public Health Institute. Published by Elsevier Ireland Ltd. This is an open access article
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Cardiovascular disease (CVD) is the leading cause of death and dis-
ability worldwide. Imbalances in the autonomous nervous systemmea-
sured by heart rate variability (HRV), a non-invasive measure of the
autonomic regulation of cardiac rhythm, have been associated with in-
creased cardiovascular morbidity and mortality [1–3]. A wide range of
health conditions and CVD risk factors are associated with decreased
HRV characterized by a hyperactive sympathetic and a hypoactive para-
sympathetic system [1,4]. The understanding of modiﬁable lifestyle fac-
tors like smoking, physical inactivity and overweight is thereby of
particular public health concern. Overweight and especially obese per-
sons are more prone to different CVD outcomes [5]. Several studies
have documented reduced HRV among overweight and obese individ-
uals, which indicated the involvement of autonomic disturbances in
mechanisms promoting arrhythmia and sudden death [4,6]. A hypothe-
sized pathophysiological mechanism underlying individual variation in
the functioning of the autonomous nervous system is oxidative stress.
Epidemiologic support for an association between oxidative stress and
the autonomic control of the heart and therefore HRV is still limited.
But the hypothesis is supported by the inverse HRV associationwith ge-
netic variants related to oxidative defenses and inﬂammation [7–9].
An interesting candidate to further explore the oxidative stress path-
way in HRV and susceptibility to its risk factors isNFE2L2 (nuclear factor
erythroid 2-like 2; also known as NRF2), a gene encoding the transcrip-
tion factor Nrf2 which is known to be a master regulator of the antiox-
idant response by binding to the antioxidant response elements (ARE)
[10]. Nrf2 induces the expression of a wide array of detoxifying, anti-
inﬂammatory, cytoprotective and antioxidant enzymes in response to
oxidative stress [11]. A recent study has shown that NFE2L2 gene vari-
ants are associated with reduced risk of all-cause, cardiovascular and
COPD mortality in humans [12]. An association with cardiovascular
mortality was particularly found for the tagging single nucleotide poly-
morphism (SNP) (rs2364723) [12].
The aim of our study was to investigate whether a variation in the
NFE2L2 gene is associated with the strength of the previously reported




This study complies with the declaration of Helsinki. Ethical approval for the
SAPALDIA study was given by the Swiss Academy of Medical Sciences, the national ethics
committee for clinical research (UREK, Project Approval Number 123/00) and the Canton-
al Ethics Committees for each of the eight examination areas (Ethics commissions of the
cantons Aargau, Basel, Geneva, Grisons, Ticino, Valais, Vaud and Zurich). Participants
were required to givewritten consent before any part of the health examinationwas con-
ducted either globally (for all health examinations) or separately for each assessment.
2.2. Study population
The SAPALDIA cohort was designed to investigate the effects from environmental and
lifestyle exposures on respiratory and cardiovascular health in the Swiss adult population.
Details of its design, objectives and study population have already been well described
[13,14]. In brief, a random sample of Swiss adults aged between 18 and 60 years was re-
cruited from eight areas in Switzerland featuring distinct geographic and environmental
conditions. After written invitation, a total of 9651 persons participated in SAPALDIA 1.
They received intensive health examinations and had to answer to a detailed health inter-
view [14]. The study population assessed at baseline in 1991 (SAPALDIA 1) has been follow-
ed up twice, in 2002/2003 (SAPALDIA 2) [13] and 2010/2011 (SAPALDIA 3). In both follow-
up assessments, interviews and examinations were repeated by trained ﬁeldworkers and
the cardiovascular focus of the study was strengthened. Additionally, bio specimens and
blood pressure measurements were collected. Questionnaire information was provided
by 8047 original participants in SAPALDIA2and by 6088 original participants at SAPALDIA3.
For 6055 participants in SAPALDIA 2 genetic data was available [13]. From the 4415
SAPALDIA 2 follow-up participants 50 years and older, a random sample of 1846was invit-
ed to participate in a 24-h electrocardiogram (ECG) recording. In SAPALDIA 3 a sample of
2222 participants aged 50 years and older participated in the ECGmeasurements. After ex-
clusion of recordings with insufﬁcient quality and insufﬁcient information on model co-
variables, we assessed effects of obesity and a NFE2L2 gene variant on HRV in 1472SAPALDIA 2 participants and in 1235 SAPALDIA 3, 508 were already part of the SAPALDIA
2HRV sample and therefore provided repeat HRV information for assessing the sustainabil-
ity of the observed cross-sectional associations.
2.3. HRV measurements and deﬁnition
The 24-h electrocardiogram (Holter) recording was realized using digital devices
(Aria; Del Mar. Medical Systems, Irvine, CA, USA) with a resolution of 128 samples/s
[15]. Every selected participant who had given consent after a detailed health interview,
was equipped with a recorder. Participants were asked to follow their regular daily life
and to complete a time–activity diary during the recording time. The three leads (V1, al-
tered V3 with the electrode on the left midclavicular line on the lowest rib, and altered
V5 with the electrode on the left anterior axillary line on the lowest rib) were recorded
over 24 h. The mean duration of the SAPALDIA 2 Holter recordings (N= 1472) was 22.3
(SD 2.1) hours (SAPALDIA 3: 23.6 (SD 0.9) hours; N=1235). All recordingswere scanned
by StrataScan 563 (Del Mar. Medical Systems) and interpreted using the interactive
method, with a ﬁnal visual check on the full disclosure. The length of each RR interval
was manually validated. Only normal-to-normal (NN) intervals were used with intervals
excluded because of ectopy and artifacts. As summarymeasure of HRV and to reducemul-
tiple testing problems, we a priori decided to examine the time domain parameter stan-
dard deviation of all normal RR (NN) intervals (SDNN) over 24 h. SDNN reﬂects both
sympathetic and parasympathetic activity and therefore provides an index of total HRV
[16]. To avoid a biased result caused by themethacholine challenge, whichwas performed
before the Holter recording as part of the SAPALDIA 2 lung function assessment, the ﬁrst
2 h of all recordings were excluded.
2.4. Deﬁnitions of weight categories by BMI
Height and weight (participants did not wear shoes or coats) were measured in the
SAPALDIA centers. Body mass index (BMI) was calculated as weight (kilograms) divided
by height (meters) squared. In this study, following the WHO deﬁnition from 2008, we
classiﬁed persons with a BMI below 18.5 kg/m2 as underweight, persons with a BMI
from 18.5 to 25 kg/m2 as normal weight, persons with a BMI from 25 kg/m2 to 30 kg/m2
as overweight and above 30 kg/m2 as obese. Participants with severe underweight (BMI
below 17 kg/m2) and severe overweight (BMI above 45 kg/m2) were identiﬁed as outliers
and excluded from the analysis (SAPALDIA2, N = 7; SAPALDIA 3, N = 7).
2.5. Covariate information
Information on active and passive smoking, alcohol consumption and physical exer-
cise was assessed by questionnaires. All blood marker measurements were conducted at
the Institute of Clinical Chemistry at the Zürich University Hospital, Switzerland.
2.6. Selection of NFE2L2 genetic variants and genotyping
The single functional nucleotide polymorphism (SNP) in the NFE2L2 gene locus
rs2364723 was a priori selected as the gene variant of interest. This SNP has shown to
be associated among other phenotypes also with cardiovascular mortality [12]. The
genotyping call rate for the rs2364723 SNP was 96.7% and the minor allele frequency
(MAF) was 29%.
Genomic DNA was isolated from EDTA-buffered whole blood using PUREGENETM
DNA Puriﬁcation Kit (GENTRA Systems, Minneapolis, USA) [13]. The SNP was assessed
using the Sequenom's MassARRAY® system (Sequenom, San Diego, USA) by performing
iPLEX® single base primer extension and matrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry as described elsewhere [17]. For genotyping quality-
control, a random selection of N5% of the sampleswere genotyped twice and the genotyp-
ing results agreed to 100%.
2.7. Statistical analysis
Hardy–Weinberg genotypic expectations were tested via an exact test in the total
SAPALDIA population (n = 6055), irrespective of HRV measurement, using the STATA
command genhwi (STATA version 12; StataCorp, College Station, TX, USA).
The SAPALDIA subpopulation for this study is consistent with two previous studies on
HRV [7,18]. We used repeated cross-sectional analysis, to combine SAPALDIA 2 and
SAPALDIA 3 data, including the whole population (N = 2707) with HRV measurements
at SAPALDIA 2 and/or SAPALDIA 3.We usedmultivariablemixed linear regressionmodels
to assess the cross-sectional associations of obesity and aNFE2L2 gene variant with HRV in
participantswithHRVmeasurements at both SAPALDIA follow-up assessments (N=508)
in order to assess the sustainability of the observed associations within the same individ-
uals. HRV was log-transformed and covariates were chosen in accordance with previous
analyses [18]: sex (male as reference), age (years), age2, body mass index (BMI, kg/m2),
BMI2, smoking status (never as reference, ever), daily exposure to environmental tobacco
smoke (ETS, none as reference, b3 h, N3 h), daily alcohol consumption (b1 drink as refer-
ence, ≥1 drink), weekly physical activity (to the point of getting out of breath or sweating)
(none as reference, between½ and 2 h, N2 h). Participant id and study area were included
as a random factor to adjust for potential residual clustering of data within subject and the
eight examination areas of SAPALDIA. The estimate of the overall effect of BMI on SDNN
was derived from the regression model described above. Effect estimates are presented
as crude and adjusted differences in geometric means of SDNN. Differences in the
Fig. 1.Adjusteda geometricmean (GM) of SDNN as a function of BMI of participantswith a
HRV measurement at SAPALDIA 2 and/or SAPALDIA 3 (N = 2707). Abbreviations: GM,
geometric mean; SDNN, standard deviation of all NN intervals (units ms); BMI, body
mass index; 95%CI, 95%-conﬁdence interval. aModels were adjusted for gender, age, age
squared, BMI, BMI squared, smoking status, environmental tobacco smoke exposure,
alcohol consumption, physical activity and area (random factor).
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(i.e., 20, 25, 30, 35 and 40 kg/m2) and the entire study population were expressed in per-
cent (Delta %). To model the interaction between BMI and the NFE2L2 variant, we entered
genotype-speciﬁc terms of BMI (i.e., having the value 0 in all subjects with another geno-
type) into the covariate-adjusted mixed linear models. The genotype-speciﬁc effect esti-
mates represent a percent change in SDNN calculated for the difference from the 90th to
the 10th percentile of BMI to illustrate the negative association between SDNN and BMI.
In sensitivity analyses, we assessed the independence of the observed interactions
from heart rate by including it into the model as potential confounder. Based on previous
evidence, we additionally tested several subgroups for effect modiﬁcation by running the
repeated cross-sectional interaction model in following subgroups: males/females,
smokers/non-smokers, persons reporting no intake/intake of any heart medication.
As this is an exploratory study investigating potential inﬂammatory mechanisms
through a genetic key marker of inﬂammatory response represented by one SNP
(rs2364723) in this gene, selected a priori, we did not adjust for multiple testing [19].
All testswere two-sidedwith a signiﬁcance level of 0.05. Statistical analyseswere per-
formed using STATA, version 12 (StataCorp. 2011. Stata Statistical Software: Release 12.
College Station, TX: StataCorp LP.
3. Results
In Table 1we show the characteristics of the analyzed study popula-
tion for SAPALDIA 2 and SAPALDIA 3. In SAPALDIA 2, 50.5% and in
SAPALDIA 3, 50.6% of the subjects included in the study were females.
Mean age was 60.4 years (SD 6.2) and 63.1 years (SD 7.5), respectively.
55.2% and 52.2% were ever smokers (current and ex-smokers), 21.1%,
11.2% were exposed to second hand smoke, 46.3% and 44.6% were
regular alcohol drinkers, 41.7% and 38.5% were physically inactive,
respectively. The mean BMI of the participants was 26.7 kg/m2Table 1
Characteristics of the study population, the SAPALDIA cohort.
Characteristics SAPALDIA 2
all (n = 1472)
SAPALDIA 3
all (n = 1235)a
Gender
Men 729 49.5 % 610 49.4 %
Women 743 50.5 % 625 50.6 %
Age 60.4 ± 6.2 63.1 ± 7.5
Lifestyle factors
Smoking status
Never Smokers 659 44.8 % 591 47.9 %
Ever Smokers 813 55.2 % 644 52.1 %
ETS exposure
None 1162 78.9 % 1097 88.8 %
b3 h/day 203 13.8 % 104 8.4 %
≥3 h/day 107 7.3 % 34 2.8 %
Alcohol
b1 glass/day 790 53.7 % 684 55.4 %
≥1 glass/day 682 46.3 % 551 44.6 %
Physical activity
None 614 41.7 % 475 38.5 %
0.5–1.5 h/week 481 32.7 % 457 37.0 %
≥2 h/week 377 25.6 % 303 24.5 %
Cardiovascular health
SDNN [ms]b 132.2 ± 2.9 132.0 ± 3.6
Heart rate (bpm) 74.1 ± 9.3 74.2 ± 8.9
SBP (mmHG) 132.1 ± 19.4 135.5 ± 18.4
DBP (mmHG) 81.7 ± 10.6 79.7 ± 10.2
BMI (kg/m2) 26.7 ± 4.2 26.5 ± 4.4
Obesity
Underweight 7 0.5 % 7 0.6 %
Normal weight 543 36.9 % 487 39.4 %
Overweight 628 42.7 % 512 41.5 %
Obese 294 20.0 % 229 18.5 %
NFE2L2 polymorphism
SNP: rs2364723
GG 744 50.5 % 614 49.7 %
GC 599 40.7 % 518 41.9 %
CC 129 8.8 % 103 8.3 %
Abbreviations: ETS, environmental tobacco smoke exposure; SDNN, standard deviation of
all NN intervals; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI,
bodymass index; SNP, single nucleotide polymorphism. Values shown are counts andper-
centages for categorical variables andmeans± standarddeviation for numerical variables.
a 508 of the 1235 SAPALDIA 3 participants were already included in SAPALDIA 2. b SDNN is
calculated as crude geometric mean with 95%-conﬁdence intervals (CI).(SD 4.2) and 26.5 kg/m2 (SD 4.4), respectively. Almost all study partici-
pants are Caucasians.
Applying the cross-sectional repeated measure model in the whole
study population (n = 2707) we observed a continuous decrease of
the adjusted average SDNN as a function of BMI, starting at a BMI of
about 25 kg/m2 (Fig. 1). Normal weight persons (with a BMI between
20 and 25 kg/m2) exhibited a higher than average adjusted geometric
mean of SDNN (Table 2). Obese persons (BMI N 30 kg/m2) exhibited a
lower mean SDNN, decreasing continuously with increasing BMI. Per-
sons with a BMI of 40 kg/m2, had on average a−21.3% lower adjusted
geometric mean of SDNN of 103.9 ms (95%CI: 98.0 ms to 109.8 ms).
The cross-sectional associations at SAPALDIA 2 and SAPALDIA 3 wereTable 2
Crude and adjusteda geometric means (GM) of SDNN by BMI of participants with a HRV
measurement at SAPALDIA 2 and/or SAPALDIA 3 (N = 2707) and of participants with
HRV measurements at both surveys (N= 508).
Crude GM, 95%CI Delta %b Adj. GM, 95%CIa Delta %b
SAPALDIA 2/3 combined (N = 2707)
Overall 132.1 129.1 135.0 132.0 129.9 134.2
BMI = 20 136.4 132.0 140.8 3.3% 137.1 133.3 141.0 3.9%
BMI = 25 133.9 131.0 136.9 1.4% 134.0 131.9 136.0 1.4%
BMI = 30 126.8 123.7 129.8 −4.0% 126.9 124.6 129.2 −3.9%
BMI = 35 115.7 112.0 119.3 −12.4% 116.6 113.5 119.7 −11.7%
BMI = 40 101.7 95.7 107.8 −23.0% 103.9 98.0 109.8 −21.3%
SAPALDIA 2 (N = 508)
Overall 134.4 130.1 138.8 134.7 131.3 138.2
BMI = 20 138.8 130.7 146.9 3.2% 140.7 132.9 148.5 4.7%
BMI = 25 135.7 131.5 139.9 0.9% 136.1 132.9 139.4 1.3%
BMI = 30 130.4 125.5 135.3 −3.0% 130.7 126.5 134.8 −2.8%
BMI = 35 123.2 116.0 130.3 −8.4% 124.4 117.8 131.0 −7.5%
BMI = 40 114.4 100.1 128.7 −14.9% 117.6 103.2 131.9 −12.6%
SAPALDIA 3 (N = 508)
Overall 132.5 127.9 137.1 132.2 128.0 136.4
BMI = 20 137.0 128.5 145.4 3.4% 138.2 130.0 146.5 4.6%
BMI = 25 134.9 130.3 139.4 1.8% 134.6 130.5 138.7 1.8%
BMI = 30 126.8 121.8 131.7 −4.3% 126.8 122.2 131.4 −4.1%
BMI = 35 113.8 107.7 120.0 −14.1% 115.5 109.6 121.4 −12.6%
BMI = 40 97.6 86.9 108.3 −26.4% 101.7 91.1 112.4 −23.0%
Abbreviations: GM, geometric mean; SDNN, standard deviation of all NN intervals
(units ms); BMI, body mass index; 95%CI, 95%-conﬁdence interval.a adjusted for gender,
age, age squared, BMI, BMI squared, smoking status, environmental tobacco smoke expo-
sure, alcohol consumption, physical activity and area (random factor). b Delta % represents
the percent difference in the geometric mean of SDNN, between the respective group of
persons and the entire study sample.
Table 3
Percent change (PC90th–10th) in SDNNa estimated for the difference from the 90th to the
10th percentile of BMI by the NFE2L2 polymorphism (rs2364723) of participants with a
HRVmeasurement at SAPALDIA 2 and/or SAPALDIA 3 (N=2707) and of participantswith
HRV measurements at both surveys (N = 508).
24-h SDNN
Genotype N PC10th-90thb CIlower CIupper pinteractionc
SAPALDIA 2/3 (N = 2707)
rs2364723
GG 1358 −11.26 −7.68 −14.70 0.014
GC 1117 −7.43 −3.56 −11.15
CC 232 −20.70 −12.33 −28.28
SAPALDIA 2 (N = 508)
rs2364723
GG 247 −7.28 0.82 −14.74 0.434
GC 212 −6.42 1.65 −13.85
CC 49 −17.42 −1.46 −30.80
SAPALDIA 3 (N = 508)
rs2364723
GG 247 −14.00 −6.51 −20.89 0.100
GC 212 −7.46 0.69 −14.95
CC 49 −19.86 −4.07 −33.06
Abbreviations: SDNN, standard deviation of all NN intervals (units ms); BMI, body mass
index; PC, percent change; CI, conﬁdence interval. a Models were adjusted for gender,
age, age squared, BMI, BMI squared, smoking status, environmental tobacco smoke expo-
sure, alcohol consumption, physical activity and area (random factor). b The percent
change (PC90th–10th) in SDNN represents the difference calculated from the 90th to the
10th percentile of BMI by the NFE2L2 genotype. c p-values of interaction effects of the
NFE2L2 (rs2364723) polymorphism with BMI on SDNN.
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(Table 2 and Figs. S1 and S2).
In Table 3 and Fig. 2, we present the adjusted geometricmeans (GM)
of SDNN as a function of BMI by the NFE2L2 variant, measured across
two surveys almost 10 years apart. SDNN was inversely related with
BMI in all 3 genotype groups. While this relation was very similar be-
tween the 90th and the 10th percentile of BMI among participants
carrying only one or no C-allele (GC:−7.43; 95%-conﬁdence interval
(95%CI): −3.56 to−11.15; GG: −11.26%; 95%CI:−7.68. to −14.7),
the respective gradient was much steeper for participants carrying
homozygously the minor C-allele (CC:−20.7%; 95%CI:−12.33 to −
28.28). The p of interaction was =0.014. The cross-sectional genotype
speciﬁc associations of BMI with HRV were sustainable, albeit at a
lower statistical signiﬁcance level, within individuals who provided
HRV data at both SAPALDIA follow-up assessments (N = 508)
(Table 3, Figs. S3 and S4).Fig. 2. Adjusteda geometric means (GM) of SDNN as a function of BMI by the NFE2L2
(rs2364723) genotype of participants with a HRV measurement at SAPALDIA 2 and / or
SAPALDIA 3 (N = 2707). Abbreviations: GM, geometric mean; SDNN, standard
deviation of all NN intervals (units ms); BMI, body mass index. a Models were adjusted
for gender, age, age squared, BMI, BMI squared, smoking status, environmental tobacco
smoke exposure, alcohol consumption, physical activity and area (random factor).In sensitivity analyses applying the repeated cross-sectional interac-
tionmodel, we did not ﬁnd a particular difference to the observed inter-
action results across all tested subgroups (males, females, smokers, non-
smokers; persons reporting no intake/intake of any heart medication)
(data not shown). The observed interactions remained almost unaltered
after adjusting for heart rate (Table S1).
4. Discussion
This is the ﬁrst study to show that the inverse and heart rate inde-
pendent association between BMI andHRV ismodiﬁed by a genetic var-
iation in NFE2L2, an important regulator of anti-oxidative and anti-
inﬂammatory pathways. The decrease in SDNN started with beginning
overweight at a BMI of about 25 kg/m2 and was especially pronounced
in obese persons. The patterns according to which the association be-
tween SDNN and BMI was modiﬁed by the NFE2L2SNP rs2364723
were sustained over two follow-up surveys almost 10 years apart, be-
tween and within individuals, for a phenotype that exhibits inter-
individual and intra-individual variability over time.
4.1. Comparison with other studies
For the development of coronary artery disease (CAD), behavioral,
physiological and environmental risk factors such as active and passive
smoking, obesity, hypercholesterolemia, arteriosclerosis, physical inac-
tivity, hypertension, diabetes, depression and air pollution, are well
known. A better understanding of the physiological pathways linking
these risk factors to the development of CAD, remains an important
public health issue. These risk factors alter autonomic function
measured as HRV [18,20–23], which itself has been associated with
future cardiovascular events or mortality in both, the general popula-
tion and patients with heart disease. Numerous epidemiological studies
have shown that the attenuation of HRV is particularly enhanced in
susceptible populations (persons exhibiting obesity, diabetes,metabolic
syndrome) [24–26]. These risk factors and conditions are also associated
with proinﬂammatory cytokines and markers of oxidative stress
[27–29].
Obesity as one of the well-known cardiovascular risk factors has
been reported to induce systemic oxidative stress,while oxidative stress
itself has been associated with an irregular production of adipokines
contributing to the development of the metabolic syndrome [30].
Biomarkers of oxidative damage were reported to be higher in obese
persons and to correlate directly with BMI, body fat, triglyceride levels
and low-density lipoprotein oxidation, and moreover antioxidant
defense markers were lower in obese persons [31].
Evidence supporting the role of systemic low grade inﬂammation
and oxidative stress in mediating genetic susceptibility of the autonom-
ic nervous system is sparse. TheNormative Aging Study found that func-
tional genetic variations in GSTM1 and HMOX1, both related to defenses
against oxidative stress, modify the effects of PM2.5 on HRV [32]. A pre-
vious study in the SAPALDIA population found a genetic variation in one
of themajor pro-inﬂammatoy cytokines, IL6, to alter HRV and its associ-
ation with long-term exposure to air pollution [7]. In another SAPALDIA
publication we reported a modifying effect of the antioxidative GSTM1
gene polymorphisms on the association of HRV with the inﬂammatory
risk factor second-hand smoke [9]. Howden et al. showed signiﬁcant
greater reductions in HRV in Nrf2−/− compared with Nrf2+/+ mice
when exposed to environmental stressors like particulate matter
(PM), hence providing evidence that theNFE2L2 gene is functionally rel-
evant and protective for cardiovascular alterations. They further con-
cluded that Nrf2 signaling pathway may hence be an important
determinant in defense against severe and moderate oxidative stress
[33].
The association of obesity with HRV has not been consistently re-
ported [24,34–36]. Most of the studies were looking at subgroups and
examined different obesity parameters. A recent study found a
345M. Adam et al. / International Journal of Cardiology 228 (2017) 341–346decreasedHRV during stressful conditions, with the greatest HRV atten-
uation in the obese group [24].
A study in children found that obesity was associated with impaired
cardiac autonomic modulation with signiﬁcantly lower HRV [37]. A
study which speciﬁcally assessed the roles of overall adiposity (mea-
sured by BMI) and abdominal adiposity (measured by waist circumfer-
ence) on HRV found only abdominal adiposity to be associated with
decreased HRV, while no such effect was found for overall adiposity
[36]. A study of Aeschbacher et al. showed that adopting a healthy life-
style, including to keep a normal weight, was associated with a greater
HRV [38]. In one of our own studies, the already mentioned association
between HRV and second hand smoke was particularly pronounced in
obese persons [9]. Nevertheless, several studies did not ﬁnd an associa-
tion between HRV and BMI [39–41].
The Nrf2-mediated regulation of cellular antioxidant and anti-
inﬂammatory mechanisms plays an important role in defense against
oxidative stress and inﬂammation [10,42,43]. Polymorphisms in the
Nrf2 signaling pathway have been shown to lead to differential suscep-
tibility to diseases. Evidence suggests that NFE2L2 and several down-
stream genes have an essential protective role in the lung against
oxidative stress from environmental pollutants and toxicants such as
cigarette smoke [44]. A study in 69 chronic obstructive pulmonary dis-
ease (COPD) patients showed functional haplotypes in the promoter re-
gion of NFE2L2 to affect the gene's activity and to be associatedwith the
severity and the development of respiratory failure in COPD [45].
Hampel et al. observed the repolarization parameter Bazett-corrected
QT interval (QTc) to be prolonged in association with increases in par-
ticulate matter levels, with stronger associations among participants
with at least one minor allele of the NFE2L2 SNP rs2364725 [46]. In
the population-based Vlagtwedde-Vlaardingen cohort (n = 1390) the
NFE2L2 SNP rs2364725 was associated with a lower forced expiratory
volume in 1 s (FEV1) [47]. In a follow-up study they found a protective
effect for the sameNFE2L2 SNP on cardiovascularmortality, and hypoth-
esized that different pathways involving NFE2L2 lead to pulmonary and
cardiovascular events [12]. Other studies provided evidence thatNFE2L2
is important to preserve a healthy endothelial phenotype and to main-
tain the functional integrity of vasculature, phenotypes also sensitive
to oxidative stress and inﬂammation [48]. There is increasing evidence
that Nrf2 is a key regulator of cardiovascular homeostasis by suppress-
ing oxidative stress, an important causative factor for the development
and progression of CAD (Targeting the Nrf2 pathway against cardiovas-
cular disease) [49]. In a recent study the NFE2L2 SNP rs2364723 has
been shown to be associated with a reduced risk of cardiovascularmor-
tality [12]. The existence or the absence of the protective effect of this
speciﬁc SNP has further been shown to be associated with different
mortality risks across different subgroups (females vs. males and
never vs. ever smokers) not including normal versus overweight per-
sons. A recent study showed that the presence of NFE2L2 and related
genes polymorphisms are associated with diabetes and obesity in Mex-
ican patients, but no association was found for the rs2364723 polymor-
phisms [50]. Additionally, a recent review showed the complex role of
Nrf2 on obesity, on one side modulating adipose tissue function (glu-
cose levels and lipid metabolism through oxidative stress defense)
and on the other side modulating adipose tissue development through
adipogenesis [51].
Altogether, our ﬁnding contributes to these results on the role of
SNP rs2364723, likely enhancing the adverse obesity effect on the
autonomous nervous system and hence affecting cardiovascular
health.
Generally the epidemiologic evidence for an association between
oxidative stress and the autonomic control of the heart is still limit-
ed, but there is some support for this hypothesis [7,9]. Additionally,
the association of chronic stimuli such as diabetes and obesity with
reduced HRV is also compatible with a reactive oxygen species
(ROS) impact on the autonomic nervous system and cardiovascular
health [52,53].4.2. Strength and weaknesses
First, a major strength of our study is the population-based design
and the detailed information available on participants. Second, we had
obtained 24-h ECG recordings twice andwere able to replicate our anal-
ysis about ten years later in the same people, suggesting that the ob-
served patterns point to chronic health effects. Third, we were able to
control for major confounding factors, including detailed information
on numerous cardiovascular risk factors, available in the SAPALDIA co-
hort. However, this study has also a number of limitations. First, the pre-
sented results refer to cross-sectional associations. Second, even though
controlling in the analysis for cardiovascular risk factors, confounding of
the gene-BMI-interaction by potential interactions between risk factors
and theNFE2L2 SNP is still possible. Third, our HRV analysis was focused
solely on the time domain parameter SDNN. Fourth, we did not have
functional information available on the NFE2L2 variant investigated
nor on the Nrf2 protein level and thus cannot draw conclusions on
how the genotype might inﬂuence Nrf2 mediated the cardiovascular
phenotypes. No independent replication of these ﬁndings has been per-
formed, but on the other hand the found associations were constant
over time.
5. Conclusions
In conclusion, this study points to an important role of overweight in
decreasing heart rate variability starting at a BMI of about 25. Further,
the observed strong modifying effect by a variation in the NFE2L2 gene
suggests the involvement of the Nrf2 related pathways in the etiology
of cardiovascular diseases. Our ﬁndings contribute to the research effort
to understand the biological long-term mechanisms mediating the car-
diovascular health effects of obesity via oxidative stress and inﬂamma-
tory pathways.
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